Zantac in global recall over ‘unacceptable’ levels of potential carcinogen
Heartburn medicine pulled by GlaxoSmithKline while it investigates source of impurity
GlaxoSmithKline is recalling the popular heartburn medicine Zantac in all markets, days after the US Food and Drug Administration (FDA) found “unacceptable” levels of probable cancer-causing impurity in the drug.
Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Regulators have been recalling some blood pressure and heart failure medicines since last year.